Impax Securities Plaintiffs Seek To Finalize $9M Deal

Law360, New York (April 15, 2009, 12:00 AM EDT) -- Plaintiffs' lawyers are seeking final approval of a $9 million settlement involving allegations that generic-drug company Impax Laboratories Inc. artificially inflated the value of its stock by making false and misleading statements about its financial results.

In a motion filed Tuesday with the U.S. District Court for the Northern District of California, lead plaintiffs' counsel Coughlin Stoia Geller Rudman & Robbins LLP said that notice of the settlement had already been sent to over 15,000 potential class members.

“Here a balance of ... factors weighs heavily...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.